BELFAST, Northern Ireland, Sept. 10, 2025 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing…
NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,…
NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,…
The free digital tool uses simulations, videos, and expert resources to start conversations and challenge assumptions about learning and thinking…
The free digital tool uses simulations, videos, and expert resources to start conversations and challenge assumptions about learning and thinking…
Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path…
Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path…
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed…
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate…
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD)…